SNCA and Parkinson disease: Thus, newer therapies for sporadic PD could be developed by investigating PARK4 patients because it is reasonable to consider that these α‐synuclein regulation mechanisms may be functional at higher levels in DA neurons derived from PARK4 patients with SNCA triplication or duplication [30].